Incident cardiovascular events among middle-age men are associated with increased risk of subsequent prostate cancer diagnosis

Abstract Introduction Prostate cancer is the second most common malignancy in men worldwide, but incidence is highly dependent on screening. Purpose We aimed to examine whether incident cardiovascular disease (CVD) events are associated with increased risk of future prostate cancer in middle-aged me...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2021-10, Vol.42 (Supplement_1)
Hauptverfasser: Fardman, A, Tiosano, S, Kaplan, A, Kalstein, M, Moshkovits, Y, Segev, S, Klempfner, R, Segev, A, Grossman, E, Maor, E
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Introduction Prostate cancer is the second most common malignancy in men worldwide, but incidence is highly dependent on screening. Purpose We aimed to examine whether incident cardiovascular disease (CVD) events are associated with increased risk of future prostate cancer in middle-aged men. Methods We evaluated asymptomatic self-referred men who participated in a screening program. All subjects were free of CVD and cancer at baseline. CVD was defined as the composite of acute coronary syndrome, percutaneous coronary intervention, or stroke. Study endpoint was the development of cancer during follow up. Cancer and mortality data were available for all subjects from national registries. Cox regression models were applied with CVD as a time-dependent covariate and death as a competing risk event. Results Final study population included 18,282 subjects. Median age was 47 years (Interquartile range [IQR] 41–54). During median follow up time of 12 years (IQR 4–17) 2,047 (11%) subjects developed CVD, 406 (2.2%) developed prostate cancer and 694 (4%) died. Compared with patients who were free of CVD or prostate cancer during follow up, risk of death was 4, 6 and 15 times higher for patients who developed CVD event, prostate cancer, or both during follow up, respectively (p
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehab724.2863